Dec 22 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL MYERS SQUIBB STRENGTHENS NEUROSCIENCE PORTFOLIO WITH ACQUISITION OF KARUNA THERAPEUTICS

* BRISTOL-MYERS SQUIBB CO - PROPOSED DEAL FOR TOTAL EQUITY VALUE OF $14.0 BILLION

* BRISTOL-MYERS SQUIBB CO: PROPOSED DEAL FOR $330.00 PER SHARE IN CASH, FOR A TOTAL EQUITY VALUE OF $14.0 BILLION, OR $12.7 BILLION NET OF ESTIMATED CASH ACQUIRED.

* BRISTOL-MYERS SQUIBB CO - TRANSACTION WAS UNANIMOUSLY APPROVED BY BOTH BRISTOL MYERS SQUIBB AND KARUNA BOARDS OF DIRECTORS

* BRISTOL-MYERS SQUIBB CO- DEAL EXPECTED TO BE DILUTIVE TO BRISTOL MYERS SQUIBB'S NON-GAAP DILUTED EARNINGS PER SHARE BY APPROXIMATELY $0.30 IN 2024

* BRISTOL-MYERS SQUIBB CO - TRANSACTION IS EXPECTED TO CLOSE IN FIRST HALF OF 2024

* BRISTOL-MYERS SQUIBB CO: EXPECTS TO FINANCE ACQUISITION WITH PRIMARILY NEW DEBT ISSUANCE

* BRISTOL-MYERS SQUIBB - TO OFFSET OPERATIONAL EXPENSES OF TRANSACTION THROUGH CONTINUED RESOURCE ALLOCATION, COST EFFICIENCIES, PORTFOLIO PRIORITIZATIO

* BRISTOL-MYERS SQUIBB CO - ACCOUNTING TREATMENT AS A BUSINESS COMBINATION OR ASSET ACQUISITION WILL BE DETERMINED UPON EXPECTED CLOSE OF TRANSACTION Source text for Eikon: Further company coverage: